高级别浆液性卵巢癌移植物中肿瘤相关巨噬细胞表达PD-L1:配对的primary与转移性肿瘤的比较
该研究评估了61例高级别浆液性卵巢癌(HGSOC)原发肿瘤及配对转移植入物的PD-L1表达,其中40例组织芯片、21例全切片,全切片病例与转移植入物配对。结果显示仅8%原发肿瘤有PD-L1表达,而74%有PD-L1阳性肿瘤相关巨噬细胞(TAM)。在16例初治病例中,13例(81.3%)原发与转移部位瘤内PD-L1表达一致;21对配对中19对(90.5%)两个部位一致。结论认为PD-L1阳性TAM在原发和转移HGSOC中常见,但肿瘤细胞PD-L1染色罕见。
要点
- 原发HGSOC中仅8%显示PD-L1表达,而74%显示PD-L1阳性TAM。
- 初治病例配对分析显示原发与转移部位PD-L1表达高度一致。
- 接受新辅助化疗与初治病例的瘤内及免疫浸润PD-L1表达无差异。
核心结论
- PD-L1阳性TAM在原发和转移性HGSOC中均常见,但肿瘤细胞PD-L1染色罕见。
- 初治标本中原发肿瘤与转移植入物的PD-L1表达高度一致。
- 需要临床试验来确定肿瘤相关染色是否与PD-1/PD-L1抑制的临床反应相关。
研究设计与样本
- 研究纳入61例原发HGSOC,其中40例采用组织芯片、21例采用全切片进行PD-L1和CD68免疫组化评估。
- 21例全切片病例均与转移植入物配对。
- 以CD68标记肿瘤相关巨噬细胞(TAM),分别对肿瘤细胞和TAM的膜性PD-L1染色进行评分。
主要发现
- 8%的原发HGSOC显示PD-L1表达,而74%显示PD-L1阳性TAM。
- 在16例初治病例中,13例(81.3%)原发与转移部位的瘤内PD-L1表达一致。
- 21对配对中,仅1例(4.8%)转移植入物无PD-L1阳性TAM,19例(90.5%)两个部位表达一致。
- 接受新辅助化疗的病例与初治病例相比,瘤内及免疫浸润PD-L1表达无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Data on PD-L1 expression in high grade serous ovarian carcinoma (HGSOC) is mixed. Some studies report robust tumor staining and others identify expression limited to tumor-associated macrophages (TAM). TAM PD-L1 expression is induced in HGSOC metastatic implants from patients who have undergone chemotherapy. However, it is unclear whether TAM acquisition of PD-L1 plays a role in treatment naïve tumors. We investigated PD-L1 expression in primary ovarian tumors and matched metastatic implants from predominantly treatment-naïve HGSOC. METHODS: Sixty one primary HGSOC were evaluated with PD-L1 and CD68 IHC: 40 on TMA and 21 on whole section. Whole section cases were matched to a metastatic implant. TAM were delineated by CD68. Membranous PD-L1 staining was scored separately for tumor cells and TAM. RESULTS: Eight percent of primary HGSOC demonstrated PD-L1 expression. In contrast, 74% showed PD-L1+ TAM. In the 16 treatment naïve cases, 13 (81.3%) demonstrated fidelity in intratumoral PD-L1 expression between the primary and metastatic site. Of the 21 matched pairs, only one case (4.8%) did not exhibit PD-L1 positive TAM in the metastatic implant and 19 (90.5%) showed fidelity across both locations. Intratumoral and immune infiltrate PD-L1 expression was not different in cases who received neoadjuvant chemotherapy compared to treatment naïve cases. CONCLUSIONS: PD-L1+ TAM are common in both primary and metastatic HGSOC however tumoral PD-L1 staining is rare. There was high fidelity of PD-L1 expression when comparing primary tumors and metastatic implants in treatment naïve specimens. Clinical trials are needed to determine whether tumor-associated staining correlates with clinical response to PD-1/PD-L1 inhibition.
引用
- Gottlieb CE, Mills AM, Cross JV, et al. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. Gynecol Oncol. 2017. PMID: 28065619. doi:10.1016/j.ygyno.2016.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。